Prader-Willi syndrome is a complex genomic imprinting disorder caused by loss of expression of paternally inherited genes in the imprinted 15q11-q13 region, most commonly through a paternal deletion, maternal uniparental disomy of chromosome 15, or an imprinting-center defect. It is characterized by a distinctive evolution from severe neonatal hypotonia and feeding difficulties in infancy to hyperphagia and progressive obesity in early childhood, accompanied by short stature, hypogonadism, intellectual disability, and characteristic behavioral and psychiatric features. Hypothalamic-pituitary dysfunction underlies many of the endocrine and appetite-regulation abnormalities, and management centers on growth hormone therapy together with strict dietary and environmental control of food access.
Ask a research question about Prader-Willi Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Prader-Willi Syndrome
creation_date: "2026-04-06T23:00:00Z"
category: Mendelian
disease_term:
preferred_term: Prader-Willi syndrome
term:
id: MONDO:0008300
label: Prader-Willi syndrome
description: >-
Prader-Willi syndrome is a complex genomic imprinting disorder caused by loss of expression
of paternally inherited genes in the imprinted 15q11-q13 region, most commonly through a
paternal deletion, maternal uniparental disomy of chromosome 15, or an imprinting-center
defect. It is characterized by a distinctive evolution from severe neonatal hypotonia and
feeding difficulties in infancy to hyperphagia and progressive obesity in early childhood,
accompanied by short stature, hypogonadism, intellectual disability, and characteristic
behavioral and psychiatric features. Hypothalamic-pituitary dysfunction underlies many of
the endocrine and appetite-regulation abnormalities, and management centers on growth
hormone therapy together with strict dietary and environmental control of food access.
parents:
- Genomic Imprinting Disorders
- Neurodevelopmental Disorders
- Obesity Syndromes
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "Autosomal dominant"
explanation: Orphanet lists autosomal dominant inheritance for familial cases with imprinting center microdeletions (~1-3% of cases).
- name: Sporadic
inheritance_term:
preferred_term: Sporadic
term:
id: HP:0003745
label: Sporadic
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "Not applicable"
explanation: Orphanet lists 'Not applicable' inheritance for PWS, mapped here to Sporadic (HP:0003745), covering the majority (~95%) of de novo cases (paternal deletion or maternal UPD).
prevalence:
- population: General population
measure_type: POINT_PREVALENCE
prevalence_class: BAND_1_9_PER_100000
rate_low: 3.0
rate_high: 10.0
percentage: 0.003-0.01
notes: >
Estimated prevalence of 1 in 10,000 to 1 in 30,000 live births across
studied populations, with no significant ethnic predilection.
evidence:
- reference: PMID:40708003
reference_title: 'The burden of illness in Prader-Willi syndrome: a systematic literature review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Prader-Willi syndrome (PWS) is a rare, genetic neurobehavioral and metabolic disorder marked by hyperphagia, behavioral challenges, and significant comorbidities, requiring a multidisciplinary approach for effective management."
explanation: Systematic literature review confirming PWS as a rare genetic disorder with significant disease burden.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "1-9 / 100 000 | Worldwide | Point prevalence | ORPHANET"
explanation: Orphanet reports worldwide point prevalence of 1-9 per 100,000.
- population: Australia
measure_type: BIRTH_PREVALENCE
prevalence_class: BAND_1_9_PER_100000
rate_per_100000: 4.0
percentage: 0.004
notes: >
Birth prevalence of approximately 1 in 25,000 live births based on
population-based surveillance study.
evidence:
- reference: PMID:12598399
reference_title: 'Birth prevalence of Prader-Willi syndrome in Australia.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thirty infants were reported to the Australian Paediatric Surveillance Unit between 1998 and 2000, a prevalence of 4 per 100,000 live births or approximately 1/25,000 live births per annum."
explanation: First population-based study estimating birth prevalence of DNA-proven PWS in Australia.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "1-9 / 100 000 | Australia | Prevalence at birth | PMID:12598399"
explanation: Orphanet epidemiology table cites Australian birth prevalence.
- population: France
measure_type: BIRTH_PREVALENCE
prevalence_class: BAND_1_9_PER_100000
rate_per_100000: 5.0
percentage: 0.005
notes: >
Birth incidence of approximately 1 in 21,000 births based on molecular
diagnosis data from 2013.
evidence:
- reference: PMID:28659150
reference_title: 'Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Birth incidence calculated for 2013 was 1/21,000 births."
explanation: French national study calculating PWS birth incidence from molecular diagnosis data.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "1-9 / 100 000 | France | Prevalence at birth | PMID:28659150"
explanation: Orphanet epidemiology table cites French birth prevalence.
- population: Japan
measure_type: BIRTH_PREVALENCE
prevalence_class: BAND_1_9_PER_100000
rate_per_100000: 7.0
percentage: 0.007
notes: >
Birth incidence of approximately 1 in 15,000 live births in the San-in
district of western Japan.
evidence:
- reference: PMID:8579217
reference_title: 'Frequency of the Prader-Willi syndrome in the San-in district, Japan.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The incidence among live-births was estimated to be 6.64 x 10(-5) (1 in 15,060 live-births) in 1980-1989"
explanation: Epidemiological study estimating PWS birth incidence in western Japan.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "1-9 / 100 000 | Japan | Prevalence at birth | PMID:8579217"
explanation: Orphanet epidemiology table cites Japanese birth prevalence.
- population: United States
measure_type: POINT_PREVALENCE
prevalence_class: BAND_1_9_PER_100000
rate_per_100000: 6.0
percentage: 0.006
notes: >
Prevalence of approximately 1 in 16,000 in North Dakota based on
statewide survey.
evidence:
- reference: PMID:2240051
reference_title: 'Prevalence study of Prader-Willi syndrome in North Dakota.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Seventeen patients were identified, 8 males, 8 females, and one patient whose sex was not specified. This suggests a prevalence rate of 1 per 16,062 in North Dakota."
explanation: State-wide prevalence study of PWS in North Dakota.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "1-9 / 100 000 | United States | Point prevalence | PMID:2240051"
explanation: Orphanet epidemiology table cites US prevalence.
has_subtypes:
- name: Type I Deletion
display_name: Type I Deletion (BP1-BP3)
description: >-
Paternal 15q11-q13 deletion spanning the larger BP1-BP3 interval. Beyond the imprinted PWS
critical region it also removes the four non-imprinted 15q11.2 BP1-BP2 genes (TUBGCP5, CYFIP1,
NIPA1, NIPA2) that a Type II deletion leaves intact; this is the molecular difference between the
two deletion classes. In a consecutive microarray-typed series of 154 individuals with PWS, Type I
accounted for 35 of 87 deletions (40.2%), so roughly a fifth to a quarter of all PWS. During rhGH
therapy no significant longitudinal change in total or obstructive apnea-hypopnea index (AHI) was
detected in this subtype over the first 3-6 months of treatment. That absent signal is not
evidence of respiratory safety: the longitudinal polysomnography subgroup is small (Type I n = 12
against Type II n = 10), the Type I obstructive-AHI change is a non-significant trend rather than
a flat result (p = 0.093), and baseline obstructive AHI was significantly higher in Type I than in
Type II (1.47 +/- 0.54 against 0.26 +/- 0.20 events/h, p = 0.001), so Type II's rise starts from a
much lower floor. The contrast is between a high-baseline group that did not move detectably and a
low-baseline group that did.
genes:
- preferred_term: SNRPN
term:
id: hgnc:11164
label: SNRPN
- preferred_term: MAGEL2
term:
id: hgnc:6814
label: MAGEL2
- preferred_term: TUBGCP5
term:
id: hgnc:18600
label: TUBGCP5
- preferred_term: CYFIP1
term:
id: hgnc:13759
label: CYFIP1
- preferred_term: NIPA1
term:
id: hgnc:17043
label: NIPA1
- preferred_term: NIPA2
term:
id: hgnc:17044
label: NIPA2
subtype_frequency: OCCASIONAL
evidence:
- reference: PMID:36901699
reference_title: "Prader-Willi Syndrome and Chromosome 15q11.2 BP1-BP2 Region: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Those with the larger 15q11-q13 Type I deletion with the absence of four non-imprinted genes (NIPA1, NIPA2, CYFIP1, TUBGCP5) from the 15q11.2 BP1-BP2 region are more severely affected compared with those with PWS having a smaller Type II deletion."
explanation: >-
States the molecular definition this subtype records - Type I is the larger deletion, and is the
one that additionally removes TUBGCP5, CYFIP1, NIPA1 and NIPA2 - which is why those four genes
are listed here and not on Type II.
- reference: PMID:36674736
reference_title: "Chromosomal Microarray Study in Prader-Willi Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thirty-five (40.2%) of 87 individuals showed typical larger 15q11-q13 Type I deletion and 52 individuals (59.8%) showed typical smaller Type II deletion."
explanation: >-
Source of the subtype_frequency band. Type I is 40.2% of deletions in a consecutively enrolled,
microarray-typed series in which deletions were 87 of 154 participants, putting Type I at about
23% of all PWS - the OCCASIONAL (5-29%) band.
- reference: PPR:PPR1289133
reference_title: 'Effects of Growth Hormone Therapy on Sleep-Disordered Breathing and Metabolic Parameters in Patients with Prader-Willi Syndrome According to Genetic Subtype'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "whereas no significant longitudinal deterioration was observed in patients with type I deletions"
explanation: >-
Reports the null longitudinal AHI result for Type I over the first 3-6 months of rhGH therapy.
Bounded as this subtype's description records: n = 12, obstructive AHI p = 0.093, and a
higher Type I baseline.
- reference: PPR:PPR1289133
reference_title: 'Effects of Growth Hormone Therapy on Sleep-Disordered Breathing and Metabolic Parameters in Patients with Prader-Willi Syndrome According to Genetic Subtype'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "higher in patients with type I deletions than in those with type II deletions"
explanation: >-
Records the baseline asymmetry that bounds the null above: Type I entered the study with a
significantly higher obstructive AHI than Type II, so the two subtypes were not comparable at
baseline.
- name: Type II Deletion
display_name: Type II Deletion (BP2-BP3)
description: >-
Paternal 15q11-q13 deletion spanning the smaller BP2-BP3 interval, which retains the four
non-imprinted BP1-BP2 genes that a Type I deletion removes. It is the more common of the two
deletion classes - 52 of 87 deletions (59.8%) in a consecutive microarray-typed PWS series. During
rhGH therapy this subtype showed significant early increases in both total and obstructive
apnea-hypopnea index over the first 3-6 months, supporting close polysomnographic monitoring
across that window. That subgroup is small (n = 10) and started from a much lower baseline
obstructive AHI than Type I (0.26 +/- 0.20 against 1.47 +/- 0.54 events/h, p = 0.001), so part of
the Type II-specific rise may reflect that floor rather than a subtype-specific susceptibility.
genes:
- preferred_term: SNRPN
term:
id: hgnc:11164
label: SNRPN
- preferred_term: MAGEL2
term:
id: hgnc:6814
label: MAGEL2
subtype_frequency: FREQUENT
evidence:
- reference: PMID:36901699
reference_title: "Prader-Willi Syndrome and Chromosome 15q11.2 BP1-BP2 Region: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Those with the larger 15q11-q13 Type I deletion with the absence of four non-imprinted genes (NIPA1, NIPA2, CYFIP1, TUBGCP5) from the 15q11.2 BP1-BP2 region are more severely affected compared with those with PWS having a smaller Type II deletion."
explanation: >-
Defines Type II as the smaller deletion that retains the four BP1-BP2 genes, which is why this
subtype lists only the imprinted-region genes.
- reference: PMID:36674736
reference_title: "Chromosomal Microarray Study in Prader-Willi Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thirty-five (40.2%) of 87 individuals showed typical larger 15q11-q13 Type I deletion and 52 individuals (59.8%) showed typical smaller Type II deletion."
explanation: >-
Source of the subtype_frequency band. Type II is 59.8% of deletions in a series where deletions
were 87 of 154 participants, putting Type II at about 34% of all PWS - the FREQUENT (30-79%) band.
- reference: PPR:PPR1289133
reference_title: 'Effects of Growth Hormone Therapy on Sleep-Disordered Breathing and Metabolic Parameters in Patients with Prader-Willi Syndrome According to Genetic Subtype'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "patients with type II deletions demonstrated significant increases in both total and obstructive AHI"
explanation: >-
Reports the Type II-specific early respiratory deterioration on rhGH. The comparison rests on 10
patients with paired polysomnography; see this subtype's description for the baseline caveat.
- name: mUPD
display_name: Maternal Uniparental Disomy (mUPD15)
description: >-
Maternal uniparental disomy of chromosome 15: two maternal copies are inherited in place of one
maternal and one paternal copy, so every paternally expressed imprinted gene at 15q11-q13 is
silenced without any deletion. Reported at 20-30% of PWS in clinical review and at 40.3% in a
consecutive microarray-typed trial cohort. Shows less respiratory sensitivity to rhGH therapy than
the deletion classes.
subtype_frequency: FREQUENT
evidence:
- reference: PMID:22237428
reference_title: "Prader-Willi syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "maternal uniparental disomy 15 (20-30%)"
explanation: Clinical review confirms mUPD accounts for 20-30% of PWS cases.
- reference: PMID:36674736
reference_title: "Chromosomal Microarray Study in Prader-Willi Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "87 (56.5%) showed the typical 15q11-q13 deletion subtypes, 62 (40.3%) showed non-deletion maternal disomy 15"
explanation: >-
Gives the higher, consecutively ascertained mUPD share that puts this subtype in the FREQUENT
(30-79%) band rather than the review's 20-30% figure.
- reference: PPR:PPR1289133
reference_title: 'Effects of Growth Hormone Therapy on Sleep-Disordered Breathing and Metabolic Parameters in Patients with Prader-Willi Syndrome According to Genetic Subtype'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "both total AHI and obstructive AHI increased significantly during the first 3-6 months of treatment, primarily among patients with deletions rather than those with mUPD"
explanation: Preprint demonstrates that mUPD cases show fewer AHI increases during rhGH therapy compared to deletion cases.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_pws_imprinted_15q_loss_hypothalamic_model
hypothesis_label: Canonical 15q11.2-q13 Paternal Imprinted Locus Loss / Hypothalamic Dysfunction Model
status: CANONICAL
description: >-
Prader-Willi syndrome is caused by loss of paternally-expressed imprinted genes in the 15q11.2-q13
region — most commonly by paternal deletion (~70%), maternal uniparental disomy (~25%), or
imprinting center defect (~3%). Loss of paternal expression of SNRPN, MAGEL2, MKRN3, NDN, and the
SNORD116 snoRNA cluster disrupts hypothalamic neurodevelopment and function, producing the
characteristic biphasic phenotype: neonatal hypotonia and failure to thrive followed in early
childhood by hyperphagia, morbid obesity, hypogonadotropic hypogonadism, short stature, intellectual
disability, and behavioral/psychiatric features. SNORD116 paternal deletion alone is sufficient to
produce the core PWS phenotype, identifying it as the critical region. Growth hormone therapy
improves body composition and stature; oxytocin and MC4R-targeted setmelanotide therapies are in
trials; MAGEL2-knockout mice recapitulate hypothalamic dysfunction and validate the imprinted-locus
/ hypothalamic-axis model.
notes: >-
Retained as CANONICAL with major qualifications.
The 2026 falcon hypothesis-search report
(kb/hypotheses/Prader-Willi_Syndrome/canonical_pws_imprinted_15q_loss_hypothalamic_model;
openscientist timed out at 3600s) finds PARTIALLY SUPPORTED.
The core 15q11.2-q13 paternal-imprinted-locus loss with
hypothalamic dysfunction explaining major phenotypes is
strongly supported by convergent human genetics and
mechanistic data. Three qualifications: (1) classic PWS
phenotypes have been reported with ATYPICAL DELETIONS
SPARING SNORD116 expression, indicating that non-SNORD116
mechanisms (e.g., SNURF-SNRPN / host transcript regulation)
can be sufficient in at least some cases — the
'SNORD116-only' minimal model is incomplete; (2)
SNORD116-only mouse and tissue-specific deletion models show
INCONSISTENT hyperphagia/obesity penetrance, implying
additional locus elements, developmental timing, environment/
diet, or modifier genes contribute; (3) deletion SUBTYPE
(Type I vs Type II) introduces additional hypothalamic
GLIAL / WHITE-MATTER / SYNAPTIC pathology not captured by a
minimal SNORD116-centric model — Type I shows microglial
phagolysosome dysfunction (elevated CD68/Iba1, reduced CTSS/
LAMP1), increased AQP4 glymphatic signatures, compromised
fornix myelin, and reduced synaptophysin; this is linked to
CYFIP1 haploinsufficiency (Type I includes CYFIP1) and may
explain Type-I severity. Growth hormone replacement
(FDA-approved), oxytocin, and MC4R-pathway setmelanotide trials
address specific axis phenotypes but no curative therapy
exists. The canonical model holds at the imprinted-locus /
hypothalamic-axis level but the molecular mechanism is
multi-component.
evidence:
- reference: PMID:40708003
reference_title: "The burden of illness in Prader-Willi syndrome: a systematic literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Prader-Willi syndrome (PWS) is a rare, genetic neurobehavioral and metabolic disorder marked by hyperphagia, behavioral challenges, and significant comorbidities, requiring a multidisciplinary approach for effective management."
explanation: >
Existing canonical mechanism citation in the dismech
knowledge base, used as the seed for the hypothesis-search
deep-research run.
- reference: PMID:22237428
reference_title: "Prader-Willi syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Prader-Willi syndrome is due to absence of paternally expressed imprinted genes at 15q11.2-q13 through paternal deletion of this region (65-75% of individuals), maternal uniparental disomy 15 (20-30%), or an imprinting defect (1-3%)."
explanation: >
Clinical review supporting the canonical imprinted-locus
mechanism and its principal molecular classes.
pathophysiology:
- name: Loss of Paternally Expressed Genes at 15q11.2-q13
description: >
Prader-Willi syndrome results from loss of function of paternally expressed
imprinted genes in the 15q11.2-q13 region. The critical genes include SNRPN,
SNORD116 cluster, MAGEL2, MKRN3, and NDN. These genes are normally expressed
only from the paternal allele due to genomic imprinting; the maternal copies
are silenced by methylation. Loss occurs through paternal deletion (~65-75%),
maternal uniparental disomy (~20-30%), or imprinting center defects (~1-3%).
cell_types:
- preferred_term: Neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: Genomic Imprinting
term:
id: GO:0071514
label: genomic imprinting
evidence:
- reference: PMID:31920975
reference_title: 'Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Prader-Willi syndrome (PWS) is a complex imprinting disorder related to genomic errors that inactivate paternally-inherited genes on chromosome 15q11-q13 with severe implications on endocrine, cognitive and neurologic systems, metabolism, and behavior."
explanation: Review confirms PWS is caused by loss of paternally expressed genes at 15q11-q13.
- reference: PMID:37386011
reference_title: 'Imprinting disorders.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Imprinting disorders (ImpDis) are congenital conditions that are characterized by disturbances of genomic imprinting. The most common individual ImpDis are Prader-Willi syndrome, Angelman syndrome and Beckwith-Wiedemann syndrome."
explanation: Comprehensive review of genomic imprinting disorders confirming PWS as a prototypical imprinting disorder.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "A rare genetic, neurodevelopmental syndrome characterized by hypothalamic-pituitary dysfunction with severe hypotonia and feeding deficits during the neonatal period followed by an excessive weight gain period with hyperphagia with a risk of severe obesity during childhood and adulthood, learning difficulties, deficits of social skills and behavioral problems or severe psychiatric problems."
explanation: Orphanet definition confirms PWS as a rare genetic neurodevelopmental syndrome with hypothalamic-pituitary dysfunction.
- reference: PMID:41683698
reference_title: 'Clinical Presentation, Genetics, and Laboratory Testing with Integrated Genetic Analysis of Molecular Mechanisms in Prader-Willi and Angelman Syndromes: A Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Prader-Willi (PWS) and Angelman (AS) syndromes were the first examples in humans with errors in genomic imprinting, usually from de novo 15q11-q13 deletions of different parent origin (paternal in PWS and maternal in AS)."
explanation: Review confirms PWS results from paternal 15q11-q13 deletions as the first recognized human imprinting disorder.
downstream:
- target: SNORD116 as Minimal Critical Region
- target: Hypothalamic Dysfunction
- target: Circadian and Epigenetic Dysregulation
- target: Scoliosis
- target: Strabismus
- target: Hypopigmentation of the Skin
- name: SNORD116 as Minimal Critical Region
description: >
The SNORD116 (HBII-85) small nucleolar RNA gene cluster has been identified
as the single locus whose loss is sufficient to produce the cardinal features
of PWS. SNORD116 post-transcriptionally increases the mRNA stability of NHLH2,
a transcription factor involved in processing prohormone convertase 1 (PC1).
Loss of SNORD116 leads to downstream deficiencies in prohormone maturation,
contributing to the pleiotropic endocrine phenotype.
cell_types:
- preferred_term: Neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: Neuropeptide Signaling Pathway
term:
id: GO:0007218
label: neuropeptide signaling pathway
evidence:
- reference: PMID:33856031
reference_title: 'Snord116 Post-transcriptionally Increases Nhlh2 mRNA Stability: Implications for Human Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "The smallest genomic region causing Prader-Willi Syndrome (PWS) deletes the non-coding RNA SNORD116 cluster; however, the function of SNORD116 remains a mystery."
explanation: Study demonstrates SNORD116 post-transcriptionally increases Nhlh2 mRNA stability, linking it to prohormone processing.
- reference: PMID:31920975
reference_title: 'Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "SNORD116 has emerged as a critical, and possibly, a determinant candidate in PWS, in the recent years."
explanation: Review identifies SNORD116 as the most critical gene in the PWS region.
downstream:
- target: Hypothalamic Dysfunction
- target: Circadian and Epigenetic Dysregulation
- name: Hypothalamic Dysfunction
description: >
Loss of 15q11.2-q13 gene products leads to hypothalamic dysfunction affecting
multiple neuroendocrine axes. This includes growth hormone deficiency, hypogonadism,
dysregulated appetite signaling (particularly involving ghrelin and oxytocin
pathways), impaired temperature regulation, and sleep abnormalities. The arcuate
nucleus is of central importance for controlling metabolism, hunger, and satiety
in PWS.
cell_types:
- preferred_term: Neuroendocrine Cell
term:
id: CL:0000165
label: neuroendocrine cell
- preferred_term: Oxytocin-Secreting Magnocellular Cell
term:
id: CL:4023108
label: oxytocin-secreting magnocellular cell
biological_processes:
- preferred_term: Regulation of Appetite
term:
id: GO:0032098
label: regulation of appetite
- preferred_term: Regulation of Growth Hormone Secretion
term:
id: GO:0060123
label: regulation of growth hormone secretion
evidence:
- reference: PMID:40136445
reference_title: 'The Role of the Arcuate Nucleus in Regulating Hunger and Satiety in Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PWS is considered a hypothalamic disease, and within the hypothalamus the arcuate nucleus (AC) is of central importance for controlling metabolism, hunger, and satiety."
explanation: Review details the role of the arcuate nucleus in PWS appetite dysregulation.
- reference: PMID:9861478
reference_title: 'Cerebrospinal fluid levels of oxytocin in Prader-Willi syndrome: a preliminary report.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These data provide further evidence for hypothalamic and oxytocinergic dysfunction in PWS."
explanation: Early study demonstrating altered CSF oxytocin levels in PWS patients, supporting hypothalamic dysfunction.
- reference: PMID:37685915
reference_title: 'Hormonal Imbalances in Prader-Willi and Schaaf-Yang Syndromes Imply the Evolution of Specific Regulation of Hypothalamic Neuroendocrine Function in Mammals.'
supports: SUPPORT
evidence_source: OTHER
snippet: "The hypothalamus regulates fundamental aspects of physiological homeostasis and behavior, including stress response, reproduction, growth, sleep, and feeding, several of which are affected in patients with Prader-Willi (PWS) and Schaaf-Yang syndrome (SYS)."
explanation: Review connecting PWS-gene loss to hypothalamic neuroendocrine dysfunction affecting feeding, growth, and reproduction.
downstream:
- target: Neonatal Hypotonia
- target: Hyperphagia
- target: Obesity
- target: Short Stature
- target: Hypogonadotropic Hypogonadism
- target: Cryptorchidism
- target: Feeding Difficulties in Infancy
- target: Dysphagia
- target: Growth Delay
- target: Infertility
- target: Osteoporosis
- target: Type II Diabetes Mellitus
- name: Circadian and Epigenetic Dysregulation
description: >
SNORD116 exhibits diurnal rhythms of DNA methylation in mouse cortex.
Loss of Snord116 disrupts these rhythmic methylation patterns, with more than
23,000 diurnally rhythmic CpGs lost or phase-shifted. This may contribute
to the sleep and circadian disturbances observed in PWS.
cell_types:
- preferred_term: Neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: Circadian Rhythm
term:
id: GO:0007623
label: circadian rhythm
evidence:
- reference: PMID:29691382
reference_title: 'Snord116-dependent diurnal rhythm of DNA methylation in mouse cortex.'
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "More than 23,000 diurnally rhythmic CpGs are identified in wild-type cortex, with nearly all lost or phase-shifted in PWS."
explanation: Mouse model demonstrates SNORD116-dependent diurnal DNA methylation rhythms disrupted in PWS.
downstream:
- target: Intellectual Disability
- target: Behavioral Abnormalities
- target: Anxiety
- target: Motor Delay
- target: Abnormal Temper Tantrums
- target: Delayed Speech and Language Development
- target: Obstructive Sleep Apnea
- target: Seizures
- target: Psychosis
- target: Attention Deficit Hyperactivity Disorder
phenotypes:
- name: Neonatal Hypotonia
category: Neurological
frequency: VERY_FREQUENT
diagnostic: true
notes: Severe muscular hypotonia present at birth with poor suck reflex and feeding difficulties.
description: >
Severe muscular hypotonia present at birth, often with poor suck reflex
and feeding difficulties requiring assisted feeding. Nearly all neonates
with PWS require specialized feeding support.
phenotype_term:
preferred_term: Neonatal hypotonia
term:
id: HP:0001319
label: Neonatal hypotonia
evidence:
- reference: PMID:40409799
reference_title: 'Prader Willi syndrome: advances in genetics.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Early manifestations include severe hypotonia, feeding difficulties, and failure to thrive in infancy, progressing to hyperphagia, obesity, intellectual disabilities, and behavioral challenges in later stages."
explanation: Review confirms severe hypotonia as an early hallmark manifestation of PWS.
- reference: PMID:41683698
reference_title: 'Clinical Presentation, Genetics, and Laboratory Testing with Integrated Genetic Analysis of Molecular Mechanisms in Prader-Willi and Angelman Syndromes: A Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PWS is characterized early with infantile hypotonia, a poor suck, and failure to thrive with hypogenitalism/hypogonadism."
explanation: Review confirms infantile hypotonia and poor suck as early PWS features.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0001252 | Hypotonia | Very frequent (99-80%)"
explanation: Orphanet lists hypotonia as very frequent (99-80%) in PWS.
- name: Hyperphagia
category: Metabolic
frequency: FREQUENT
diagnostic: true
notes: Insatiable appetite typically emerging between ages 2-8.
description: >
Insatiable appetite typically emerging between ages 2-8, leading to severe
obesity if food intake is not externally controlled. Driven by hypothalamic
dysfunction in appetite regulation. High levels of ghrelin have consistently
been reported in PWS.
phenotype_term:
preferred_term: Polyphagia
term:
id: HP:0002591
label: Polyphagia
evidence:
- reference: PMID:40136445
reference_title: 'The Role of the Arcuate Nucleus in Regulating Hunger and Satiety in Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main characteristics are muscular hypotonia, failure to thrive and feeding problems in infancy, which switch to hyperphagia in early childhood and continue into adulthood."
explanation: Review confirms the biphasic feeding pattern with hyperphagia emerging in early childhood.
- reference: PMID:40708003
reference_title: 'The burden of illness in Prader-Willi syndrome: a systematic literature review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hyperphagia contributed substantially to the disease burden, necessitating constant food security measures to prevent life-threatening complications."
explanation: Systematic review confirms hyperphagia as a major contributor to PWS disease burden.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0002591 | Polyphagia | Frequent (79-30%)"
explanation: Orphanet lists polyphagia as frequent (79-30%) in PWS.
- name: Obesity
category: Metabolic
frequency: FREQUENT
notes: >-
Develops secondary to hyperphagia if food intake is not strictly controlled;
can reach 80-90% in unmanaged cases, but early diagnosis and dietary control
lower observed prevalence, and Orphanet codes it in the Frequent (79-30%) band.
description: >
Morbid obesity develops secondary to uncontrolled hyperphagia.
Prevalence up to 80-90% in unmanaged cases. Leading cause of
morbidity and mortality in PWS.
phenotype_term:
preferred_term: Obesity
term:
id: HP:0001513
label: Obesity
evidence:
- reference: PMID:40004838
reference_title: 'Comorbidities, Endocrine Medications, and Mortality in Prader-Willi Syndrome-A Swedish Register Study.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Its main characteristics are muscular hypotonia, behavioral problems, intellectual disability, endocrine deficiencies, hyperphagia, and a high risk of morbid obesity and related comorbidities."
explanation: Swedish register study confirms high risk of morbid obesity in PWS.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0012743 | Abdominal obesity | Frequent (79-30%)"
explanation: Orphanet codes obesity (as abdominal obesity, HP:0012743) in the Frequent (79-30%) band in PWS, anchoring the FREQUENT frequency assignment.
- name: Intellectual Disability
category: Neurological
frequency: FREQUENT
diagnostic: true
notes: Mild to moderate intellectual disability with mean IQ around 60-70.
description: >
Mild to moderate intellectual disability with mean IQ around 60-70.
Characteristic cognitive profile includes relative strengths in visual-spatial
processing and weaknesses in arithmetic and sequential processing.
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
evidence:
- reference: PMID:40409799
reference_title: 'Prader Willi syndrome: advances in genetics.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Early manifestations include severe hypotonia, feeding difficulties, and failure to thrive in infancy, progressing to hyperphagia, obesity, intellectual disabilities, and behavioral challenges in later stages."
explanation: Review confirms intellectual disabilities as a feature of PWS.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0001256 | Intellectual disability, mild | Frequent (79-30%)"
explanation: Orphanet lists mild intellectual disability as frequent (79-30%) in PWS.
- name: Short Stature
category: Growth
frequency: VERY_FREQUENT
notes: Growth hormone deficiency leads to short stature if untreated.
description: >
Growth hormone deficiency leads to short stature if untreated.
Growth hormone therapy is standard of care, significantly improving
height-SDS compared to untreated patients.
phenotype_term:
preferred_term: Short stature
term:
id: HP:0004322
label: Short stature
evidence:
- reference: PMID:41224350
reference_title: 'Long-term growth hormone effects in Prader-Willi syndrome: A systematic review and meta-analysis.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Patients on GH experienced a more pronounced increase in height-SDS compared to those who have not received GH."
explanation: Meta-analysis demonstrates significant short stature in PWS correctable with growth hormone therapy.
- reference: PMID:40409799
reference_title: 'Prader Willi syndrome: advances in genetics.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Additional features include growth hormone deficiency, short stature, delayed puberty, and other endocrine abnormalities."
explanation: Review confirms short stature as a feature of PWS.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0004322 | Short stature | Very frequent (99-80%)"
explanation: Orphanet lists short stature as very frequent (99-80%) in PWS.
- name: Hypogonadotropic Hypogonadism
category: Endocrine
frequency: FREQUENT
diagnostic: true
notes: Genital hypoplasia, cryptorchidism in males, delayed or incomplete puberty, and infertility.
description: >
Hypogonadotropic hypogonadism with genital hypoplasia, cryptorchidism
in males, delayed or incomplete puberty, and infertility in most cases.
Driven by deficient GnRH pulsatility.
phenotype_term:
preferred_term: Hypogonadotropic hypogonadism
term:
id: HP:0000044
label: Hypogonadotropic hypogonadism
evidence:
- reference: PMID:41683698
reference_title: 'Clinical Presentation, Genetics, and Laboratory Testing with Integrated Genetic Analysis of Molecular Mechanisms in Prader-Willi and Angelman Syndromes: A Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PWS is characterized early with infantile hypotonia, a poor suck, and failure to thrive with hypogenitalism/hypogonadism."
explanation: Review confirms hypogonadism as a characteristic feature of PWS from early life.
- reference: PMID:31920975
reference_title: 'Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A key feature of the syndrome is the hypothalamic dysfunction that may be the basis of several endocrine symptoms."
explanation: Review links hypogonadism to hypothalamic dysfunction in PWS.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000135 | Hypogonadism | Frequent (79-30%)"
explanation: Orphanet lists hypogonadism as frequent (79-30%) in PWS.
- name: Behavioral Abnormalities
category: Behavioral
frequency: FREQUENT
notes: Includes temper tantrums, stubbornness, skin picking, obsessive-compulsive features.
description: >
Characteristic behavioral phenotype including temper tantrums, stubbornness,
skin picking, obsessive-compulsive features, and emotional lability.
Patients with deletions tend to have more pronounced behavioral issues,
while UPD patients show increased risk of psychotic illness in adulthood.
phenotype_term:
preferred_term: Atypical behavior
term:
id: HP:0000708
label: Atypical behavior
evidence:
- reference: PMID:41677631
reference_title: 'Genomic Imprinting, Epigenetic Dysregulation, and Neuropsychiatric Mechanisms in Prader-Willi Syndrome: A Multi-Level Integrative Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "deletion-type PWS is primarily associated with impaired neuronal maturation, altered serotonergic signaling, and locus-specific transcriptional dysregulation."
explanation: Review details genotype-specific behavioral and neuropsychiatric mechanisms in PWS.
- reference: PMID:40004838
reference_title: 'Comorbidities, Endocrine Medications, and Mortality in Prader-Willi Syndrome-A Swedish Register Study.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Its main characteristics are muscular hypotonia, behavioral problems, intellectual disability, endocrine deficiencies, hyperphagia, and a high risk of morbid obesity and related comorbidities."
explanation: Swedish register study confirms behavioral problems as a main characteristic of PWS.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000708 | Atypical behavior | Frequent (79-30%)"
explanation: Orphanet lists atypical behavior as frequent (79-30%) in PWS.
- name: Cryptorchidism
category: Genitourinary
frequency: VERY_FREQUENT
notes: Undescended testes in males, present from birth.
description: >
Cryptorchidism is a frequent finding in males with PWS,
reflecting the hypogonadotropic hypogonadism.
phenotype_term:
preferred_term: Cryptorchidism
term:
id: HP:0000028
label: Cryptorchidism
evidence:
- reference: PMID:41683698
reference_title: 'Clinical Presentation, Genetics, and Laboratory Testing with Integrated Genetic Analysis of Molecular Mechanisms in Prader-Willi and Angelman Syndromes: A Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PWS is characterized early with infantile hypotonia, a poor suck, and failure to thrive with hypogenitalism/hypogonadism."
explanation: Review confirms genital hypoplasia (including cryptorchidism) as an early feature of PWS.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000028 | Cryptorchidism | Very frequent (99-80%)"
explanation: Orphanet lists cryptorchidism as very frequent (99-80%) in PWS.
- name: Scoliosis
category: Musculoskeletal
frequency: FREQUENT
notes: Common complication, may require surgical correction.
description: >
Scoliosis is a common musculoskeletal complication in PWS,
occurring in a significant proportion of patients and sometimes
requiring surgical intervention.
phenotype_term:
preferred_term: Scoliosis
term:
id: HP:0002650
label: Scoliosis
evidence:
- reference: PMID:20301505
reference_title: 'Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Characteristic facial features, strabismus, and scoliosis are often present."
explanation: GeneReviews entry confirms scoliosis is often present in PWS.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0002650 | Scoliosis | Frequent (79-30%)"
explanation: Orphanet lists scoliosis as frequent (79-30%) in PWS.
- name: Obstructive Sleep Apnea
category: Respiratory
frequency: FREQUENT
notes: Related to obesity and hypothalamic dysfunction.
description: >
Obstructive sleep apnea is a frequent complication of PWS,
related to both obesity and central hypothalamic dysfunction.
Both central and obstructive forms of sleep apnea occur in PWS.
phenotype_term:
preferred_term: Obstructive sleep apnea
term:
id: HP:0002870
label: Obstructive sleep apnea
evidence:
- reference: PMID:41574892
reference_title: 'Age Does Not Affect Respiratory Characteristics in Children With Prader-Willi Syndrome Before and After Growth Hormone Therapy.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Children with Prader-Willi syndrome (PWS) are at increased risk of both central (CSA) and obstructive sleep apnoea (OSA)."
explanation: Study confirms PWS children are at increased risk of both central and obstructive sleep apnea.
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0002870 | Obstructive sleep apnea | Frequent (79-30%)"
explanation: Orphanet lists obstructive sleep apnea as frequent (79-30%) in PWS.
- reference: PPR:PPR1289133
reference_title: 'Effects of Growth Hormone Therapy on Sleep-Disordered Breathing and Metabolic Parameters in Patients with Prader–Willi Syndrome According to Genetic Subtype'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "patients with type II deletions demonstrated significant increases in both total and obstructive AHI, whereas no significant longitudinal deterioration was observed in patients with type I deletions"
explanation: Preprint demonstrates that obstructive sleep apnea severity (measured by AHI) can worsen during early rhGH therapy in Type II deletion cases, requiring close polysomnographic monitoring in the first 6 months of treatment.
- name: Anxiety
category: Behavioral
frequency: VERY_FREQUENT
notes: Orphanet classifies anxiety as very frequent in PWS.
description: >
Anxiety is a very frequent behavioral feature of PWS, contributing to
the characteristic behavioral phenotype alongside temper tantrums and
obsessive-compulsive tendencies.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000739 | Anxiety | Very frequent (99-80%)"
explanation: Orphanet lists anxiety as very frequent (99-80%) in PWS.
- name: Motor Delay
category: Neurological
frequency: VERY_FREQUENT
notes: Global motor delay is a very frequent feature during early development.
description: >
Motor delay is a very frequent developmental feature of PWS,
with delayed acquisition of gross and fine motor milestones
secondary to neonatal hypotonia.
phenotype_term:
preferred_term: Motor delay
term:
id: HP:0001270
label: Motor delay
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0001270 | Motor delay | Very frequent (99-80%)"
explanation: Orphanet lists motor delay as very frequent (99-80%) in PWS.
- name: Feeding Difficulties in Infancy
category: Gastrointestinal
frequency: VERY_FREQUENT
notes: Severe feeding difficulties in the neonatal period requiring assisted feeding.
description: >
Feeding difficulties in infancy are a very frequent feature of PWS,
with poor suck reflex and failure to thrive necessitating nasogastric
tube feeding in many cases.
phenotype_term:
preferred_term: Feeding difficulties in infancy
term:
id: HP:0008872
label: Feeding difficulties in infancy
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0008872 | Feeding difficulties in infancy | Very frequent (99-80%)"
explanation: Orphanet lists feeding difficulties in infancy as very frequent (99-80%) in PWS.
- reference: PMID:28659150
reference_title: 'Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "84% needed nasogastric tube feeding for a median of 38 days."
explanation: French national study confirms most PWS neonates require nasogastric tube feeding.
- name: Dysphagia
category: Gastrointestinal
frequency: VERY_FREQUENT
notes: Swallowing difficulties contributing to neonatal feeding problems.
description: >
Dysphagia is a very frequent feature in PWS, particularly in infancy,
contributing to the characteristic neonatal feeding difficulties.
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0002015 | Dysphagia | Very frequent (99-80%)"
explanation: Orphanet lists dysphagia as very frequent (99-80%) in PWS.
- name: Growth Delay
category: Growth
frequency: VERY_FREQUENT
notes: Growth delay is very frequent, largely secondary to growth hormone deficiency.
description: >
Growth delay is a very frequent feature of PWS, reflecting
underlying growth hormone deficiency and contributing to short
stature if untreated.
phenotype_term:
preferred_term: Growth delay
term:
id: HP:0001510
label: Growth delay
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0001510 | Growth delay | Very frequent (99-80%)"
explanation: Orphanet lists growth delay as very frequent (99-80%) in PWS.
- name: Infertility
category: Endocrine
frequency: VERY_FREQUENT
notes: Infertility affects the vast majority of individuals with PWS.
description: >
Infertility is very frequent in PWS, resulting from hypogonadotropic
hypogonadism. Rare pregnancies have been reported in females.
phenotype_term:
preferred_term: Infertility
term:
id: HP:0000789
label: Infertility
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000789 | Infertility | Very frequent (99-80%)"
explanation: Orphanet lists infertility as very frequent (99-80%) in PWS.
- name: Abnormal Temper Tantrums
category: Behavioral
frequency: VERY_FREQUENT
notes: Temper tantrums are a hallmark of the PWS behavioral phenotype.
description: >
Abnormal temper tantrums are a very frequent behavioral feature
of PWS, often triggered by changes in routine, food-related
frustrations, or inability to complete activities.
phenotype_term:
preferred_term: Abnormal temper tantrums
term:
id: HP:0025160
label: Abnormal temper tantrums
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0025160 | Abnormal temper tantrums | Very frequent (99-80%)"
explanation: Orphanet lists abnormal temper tantrums as very frequent (99-80%) in PWS.
- name: Strabismus
category: Ophthalmological
frequency: FREQUENT
notes: Strabismus is a frequent ophthalmological finding in PWS.
description: >
Strabismus is a frequent feature in PWS, often presenting
in early childhood alongside other ophthalmological findings.
phenotype_term:
preferred_term: Strabismus
term:
id: HP:0000486
label: Strabismus
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000486 | Strabismus | Frequent (79-30%)"
explanation: Orphanet lists strabismus as frequent (79-30%) in PWS.
- name: Delayed Speech and Language Development
category: Neurological
frequency: FREQUENT
notes: Speech and language delays are frequent in PWS.
description: >
Delayed speech and language development is a frequent feature of PWS,
contributing to the overall neurodevelopmental profile.
phenotype_term:
preferred_term: Delayed speech and language development
term:
id: HP:0000750
label: Delayed speech and language development
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000750 | Delayed speech and language development | Frequent (79-30%)"
explanation: Orphanet lists delayed speech and language development as frequent (79-30%) in PWS.
- name: Osteoporosis
category: Musculoskeletal
frequency: FREQUENT
notes: Both osteopenia and osteoporosis are frequent in PWS.
description: >
Osteoporosis is a frequent complication in PWS, associated with
hypogonadism and growth hormone deficiency. Both osteopenia
and osteoporosis are observed.
phenotype_term:
preferred_term: Osteoporosis
term:
id: HP:0000939
label: Osteoporosis
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000939 | Osteoporosis | Frequent (79-30%)"
explanation: Orphanet lists osteoporosis as frequent (79-30%) in PWS.
- name: Hypopigmentation of the Skin
category: Dermatological
frequency: FREQUENT
notes: Relative hypopigmentation compared to family members, particularly in deletion subtypes.
description: >
Hypopigmentation of the skin is a frequent feature in PWS,
particularly in patients with the deletion subtype, attributed
to haploinsufficiency of the OCA2 gene in the 15q11-q13 region.
phenotype_term:
preferred_term: Hypopigmentation of the skin
term:
id: HP:0001010
label: Hypopigmentation of the skin
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0001010 | Hypopigmentation of the skin | Frequent (79-30%)"
explanation: Orphanet lists hypopigmentation of the skin as frequent (79-30%) in PWS.
- name: Type II Diabetes Mellitus
category: Metabolic
frequency: OCCASIONAL
notes: Diabetes risk increases with obesity and age.
description: >
Type II diabetes mellitus is an occasional but significant metabolic
complication in PWS, with risk increasing with age and severity
of obesity.
phenotype_term:
preferred_term: Type II diabetes mellitus
term:
id: HP:0005978
label: Type II diabetes mellitus
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0005978 | Type II diabetes mellitus | Occasional (29-5%)"
explanation: Orphanet lists type II diabetes mellitus as occasional (29-5%) in PWS.
- name: Seizures
category: Neurological
frequency: OCCASIONAL
notes: Seizures occur occasionally in PWS.
description: >
Seizures are an occasional neurological complication of PWS.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
explanation: Orphanet lists seizures as occasional (29-5%) in PWS.
- name: Psychosis
category: Behavioral
frequency: OCCASIONAL
notes: Psychotic episodes more common in UPD subtype, typically emerging in adolescence/adulthood.
description: >
Psychosis is an occasional but clinically important behavioral
feature of PWS, particularly in patients with the maternal UPD
genetic subtype.
phenotype_term:
preferred_term: Psychosis
term:
id: HP:0000709
label: Psychosis
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0000709 | Psychosis | Occasional (29-5%)"
explanation: Orphanet lists psychosis as occasional (29-5%) in PWS.
- name: Attention Deficit Hyperactivity Disorder
category: Behavioral
frequency: FREQUENT
description: >
ADHD symptoms are frequent in PWS, contributing to difficulties
with attention, impulsivity, and hyperactivity.
phenotype_term:
preferred_term: Attention deficit hyperactivity disorder
term:
id: HP:0007018
label: Attention deficit hyperactivity disorder
evidence:
- reference: ORPHA:739
reference_title: 'Prader-Willi syndrome'
supports: SUPPORT
snippet: "HP:0007018 | Attention deficit hyperactivity disorder | Frequent (79-30%)"
explanation: Orphanet lists ADHD as frequent (79-30%) in PWS.
genetic:
- name: SNRPN
gene_term:
preferred_term: SNRPN
term:
id: hgnc:11164
label: SNRPN
association: Causative
notes: >
Loss of paternally expressed SNRPN and the SNORD116 snoRNA cluster at 15q11.2-q13
is the primary molecular cause. Occurs via paternal deletion (~65-75%), maternal
uniparental disomy (~20-30%), or imprinting center defects (~1-3%).
evidence:
- reference: PMID:41683698
reference_title: 'Clinical Presentation, Genetics, and Laboratory Testing with Integrated Genetic Analysis of Molecular Mechanisms in Prader-Willi and Angelman Syndromes: A Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Dozens of genes and transcripts are found in the 15q11-q13 region, and may play a role in PWS, specifically paternally expressed SNURF-SNRPN and MAGEL2 genes"
explanation: Review identifies SNURF-SNRPN as a key causative gene for PWS.
- name: SNORD116
association: Causative
notes: >
Minimal critical region gene. Rare microdeletions confined to SNORD116 alone
produce the core PWS phenotype. Encodes C/D box snoRNAs involved in
post-transcriptional RNA processing.
evidence:
- reference: PMID:33856031
reference_title: 'Snord116 Post-transcriptionally Increases Nhlh2 mRNA Stability: Implications for Human Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "The smallest genomic region causing Prader-Willi Syndrome (PWS) deletes the non-coding RNA SNORD116 cluster"
explanation: Study identifies SNORD116 as the minimal critical region for PWS.
- reference: PMID:31920975
reference_title: 'Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "SNORD116 has emerged as a critical, and possibly, a determinant candidate in PWS, in the recent years."
explanation: Review confirms SNORD116 as a critical determinant gene in PWS.
- name: MAGEL2
gene_term:
preferred_term: MAGEL2
term:
id: hgnc:6814
label: MAGEL2
association: Causative
notes: >
Paternally expressed gene in the PWS critical region. Loss contributes to
hypothalamic dysfunction, particularly affecting oxytocin neuron development.
Mutations in MAGEL2 alone cause Schaaf-Yang syndrome.
evidence:
- reference: PMID:41683698
reference_title: 'Clinical Presentation, Genetics, and Laboratory Testing with Integrated Genetic Analysis of Molecular Mechanisms in Prader-Willi and Angelman Syndromes: A Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The MAGEL2 gene is involved with the regulation of retrograde transport and promotion of endosomal assembly, oxytocin and reproduction, as well as circadian rhythm, transcriptional activity control, and appetite."
explanation: Review details MAGEL2 gene functions relevant to PWS phenotype.
- name: NDN
gene_term:
preferred_term: NDN
term:
id: hgnc:7675
label: NDN
association: Causative
notes: >
Necdin, a paternally expressed gene in the PWS region. Involved in neuronal
differentiation and survival. Loss contributes to the neurodevelopmental phenotype.
evidence:
- reference: PMID:41677631
reference_title: 'Genomic Imprinting, Epigenetic Dysregulation, and Neuropsychiatric Mechanisms in Prader-Willi Syndrome: A Multi-Level Integrative Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Prader-Willi syndrome (PWS) is a rare imprinting-related neurodevelopmental disorder caused by loss of paternally expressed genes within the chromosome 15q11-q13 region, including SNORD116, MAGEL2, and NDN."
explanation: Review confirms NDN as one of the key paternally expressed genes lost in PWS.
- name: MKRN3
gene_term:
preferred_term: MKRN3
term:
id: hgnc:7114
label: MKRN3
association: Causative
notes: >
Paternally expressed gene in the PWS region involved in regulating puberty
onset timing. Loss contributes to the endocrine phenotype.
evidence:
- reference: PMID:31920975
reference_title: 'Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "While genes such as MKRN3, MAGEL2, NDN, or SNORD115 do not address the full spectrum of PWS symptoms and are less likely to have causal implications in PWS major clinical signs, SNORD116 has emerged as a critical, and possibly, a determinant candidate in PWS"
explanation: Review identifies MKRN3 as a gene in the PWS critical region, though with less direct causative role than SNORD116.
treatments:
- name: Growth Hormone Therapy
description: >
Recombinant human growth hormone is standard of care, improving growth,
body composition, muscle strength, and exercise capacity. Typically
initiated in infancy or early childhood. Meta-analysis shows significant
improvements in height-SDS and BMI-SDS.
treatment_term:
preferred_term: human growth hormone replacement therapy
term:
id: NCIT:C15599
label: Hormone Replacement Therapy
evidence:
- reference: PMID:41224350
reference_title: 'Long-term growth hormone effects in Prader-Willi syndrome: A systematic review and meta-analysis.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "GH therapy in PWS significantly improves height and IGF-1 SDS, while relatively decreasing BMI compared to no-GH, indicative of lean mass growth and healthy development."
explanation: Systematic review and meta-analysis of 41 studies demonstrates significant benefits of GH therapy in PWS.
- reference: PMID:40917343
reference_title: 'Long-term impact of growth hormone therapy on mortality and type 2 diabetes in Prader-Willi syndrome: a nationwide cohort study.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "GHT was not a direct predictor of mortality in PWS, which was instead influenced by comorbidities. However, its prolonged use was linked to increased T2DM."
explanation: Nationwide cohort study shows GH therapy does not increase mortality but requires metabolic monitoring.
- reference: PPR:PPR1289133
reference_title: 'Effects of Growth Hormone Therapy on Sleep-Disordered Breathing and Metabolic Parameters in Patients with Prader–Willi Syndrome According to Genetic Subtype'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "After 12 months, the height standard deviation score increased significantly (P < 0.001), while weight and body mass index standard deviation scores did not change significantly. Glucose and lipid parameters remained stable."
explanation: Preprint of 66 children documents that 12 months of rhGH therapy significantly improves height without metabolic adverse effects or BMI increases.
- reference: PPR:PPR1289133
reference_title: 'Effects of Growth Hormone Therapy on Sleep-Disordered Breathing and Metabolic Parameters in Patients with Prader–Willi Syndrome According to Genetic Subtype'
supports: SUPPORT
directness: INDIRECT
evidence_source: HUMAN_CLINICAL
snippet: "both total AHI and obstructive AHI increased significantly during the first 3–6 months of treatment, primarily among patients with deletions rather than those with mUPD"
explanation: >-
Supports the polysomnographic-monitoring caveat attached to rhGH therapy. Marked INDIRECT
because the quote reports the measured AHI rise, while the monitoring recommendation follows
from it by an inference step rather than being asserted. The signal is concentrated in the
deletion classes and, within them, in Type II; the Type I and Type II subtype descriptions
record the small subgroup sizes and baseline-AHI asymmetry that bound it.
- name: Dietary Management
description: >
Strict environmental control of food access is essential to prevent
life-threatening obesity. Structured meal plans with caloric restriction
combined with regular physical activity. Constant food security measures
are necessary throughout life.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: dietary intervention
term:
id: NCIT:C15447
label: Dietary Intervention
evidence:
- reference: PMID:40708003
reference_title: 'The burden of illness in Prader-Willi syndrome: a systematic literature review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hyperphagia contributed substantially to the disease burden, necessitating constant food security measures to prevent life-threatening complications."
explanation: Systematic review confirms the essential role of dietary management and food security in PWS.
- name: Hormone Replacement Therapy
description: >
Sex hormone replacement at puberty for development of secondary sexual
characteristics. Testosterone for males, estrogen/progesterone for females.
treatment_term:
preferred_term: hormone modifying therapy
term:
id: NCIT:C15445
label: Hormone Therapy
evidence:
- reference: PMID:40004838
reference_title: 'Comorbidities, Endocrine Medications, and Mortality in Prader-Willi Syndrome-A Swedish Register Study.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Somatotropin was prescribed in 63%, antidiabetics in 18%, and thyroid hormones in 16% of the PWS individuals"
explanation: Swedish register study documents extensive endocrine medication use in PWS population.
- name: Diazoxide Choline Extended-Release
description: >
K-ATP channel opener that reduces insulin secretion and modulates
hypothalamic signaling. Shows improvements in hyperphagia scores,
aggression, anxiety, and compulsivity in long-term open-label study.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: diazoxide
term:
id: CHEBI:4495
label: diazoxide
evidence:
- reference: PMID:37919617
reference_title: 'Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "DCCR administration to people with PWS was well tolerated and associated with broad-ranging improvements in the syndrome."
explanation: Long-term open-label study shows DCCR improves hyperphagia and multiple other PWS symptoms.
- name: Intranasal Oxytocin
description: >
Aimed at replacing deficient hypothalamic oxytocin. Double-blind
crossover study showed trends toward improvement in social behavior
but no statistically significant effects at day 6.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: oxytocin
term:
id: CHEBI:7872
label: oxytocin
evidence:
- reference: PMID:28371242
reference_title: 'Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The results from this study suggest that low dose intranasal oxytocin is safe for individuals with PWS and may result in reduction in appetite drive, and improvements in socialization, anxiety, and repetitive behaviors."
explanation: Double-blind crossover RCT shows trends toward improvement with intranasal oxytocin but no statistically significant effects.
- name: GLP-1 Receptor Agonists
description: >
Incretin-mediated appetite suppression using agents such as semaglutide
and dulaglutide. Emerging as potential treatment for PWS-associated obesity
and hyperphagia based on case reports and general pediatric obesity data.
Clinical trials ongoing in PWS populations.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:38321079
reference_title: 'Current and future state of pharmacological management of pediatric obesity.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This report additionally includes RCTs examining AOM for special populations of pediatric obesity including monogenic obesity, Bardet Biedl syndrome, Prader Willi syndrome, and hypothalamic obesity."
explanation: Review of anti-obesity medications includes PWS as a special population, with GLP-1 agonists among the agents discussed.
- name: Gene Reactivation Strategies
description: >
Potentially curative approaches aiming to unsilence the maternal (imprinted-off)
copy of SNORD116 and other paternally expressed PWS-region genes. Strategies
target the repressive machinery that keeps the maternal PWS locus silent —
for example inhibition of SETDB1, EHMT2/G9a, or the ZNF274/SETDB1 complex —
together with CRISPR epigenome editing (dCas9 fused to transcriptional
activators) and small-molecule epigenetic modulators. (Note: silencing
UBE3A-ATS is the Angelman-syndrome reactivation strategy and is not applicable
to PWS.) Currently in preclinical or early-phase development.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:40409799
reference_title: 'Prader Willi syndrome: advances in genetics.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Genetic advances have illuminated the role of imprinted genes, such as SNORD116, in driving the syndrome's core features, offering insights into its variability and severity."
explanation: Review discusses advances in understanding PWS genetics and emerging therapeutic strategies.
- reference: PMID:41677631
reference_title: 'Genomic Imprinting, Epigenetic Dysregulation, and Neuropsychiatric Mechanisms in Prader-Willi Syndrome: A Multi-Level Integrative Review.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These insights position PWS as a translational model for understanding how epigenetic dysregulation contributes to psychiatric risk and highlight the need for genotype-informed, mechanistically grounded research to advance biomarker development and targeted therapeutic strategies."
explanation: Review highlights the potential for targeted epigenetic therapies in PWS.
- name: Genetic Counseling
description: >
Family screening and counseling regarding recurrence risk, which varies
by genetic mechanism. Recurrence risk is typically low (<1%) for de novo
deletions, ~1% for UPD, but up to 50% for imprinting center defects
with microdeletions. Prenatal testing options available.
treatment_term:
preferred_term: Genetic Counseling
term:
id: NCIT:C15240
label: Genetic Counseling
evidence:
- reference: PMID:37051256
reference_title: 'Prader-Willi and Angelman Syndromes: Mechanisms and Management.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The molecular subtype of PWS/AS provides more accurate recurrence risk information for parents and for the individual affected with the condition."
explanation: Review confirms the importance of molecular subtyping for genetic counseling in PWS.
datasets:
- accession: ega:EGAS00001002901
title: Hypothalamic transcriptome in Prader-Willi syndrome
description: Transcriptional analysis of brain tissue from people with molecularly defined causes of obesity may highlight novel disease mechanisms and therapeutic targets. Prader-Willi syndrome (PWS) is a genetic obesity syndrome characterised by severe hyperphagia. We performed RNA sequencing of the hypothalamus from 4 individuals with PWS and 4 age-matched controls.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Prader-Willi Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
references:
- reference: PMID:20301505
title: "Prader-Willi Syndrome."
tags:
- GeneReviews
findings: []
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Review: Prader-Willi Syndrome (Changes required) · 2026-05-31T03:01:54Z · View source
GitHub review issue: https://github.com/monarch-initiative/dismech/issues/3572 Issue state: OPEN Issue created: 2026-05-31T03:01:54Z Issue updated: 2026-05-31T03:01:54Z Issue closed: not closed Review decision: Changes required Labels: review ## Completed curation review - Disease: **Prader-Willi Syndrome** - Entry: `kb/disorders/Prader-Willi_Syndrome.yaml` - Selection basis: #104 of the least-recently edited Mendelian entries - Review decision: **Changes required** - Validation stance: assumes schema, ontology-term, and reference validation pass; this is a biological/clinical/content review. ## Findings 1. Blocking: the entry has no `diagnosis` section. Add disease-specific diagnostic criteria, recommended tests/imaging/biochemical markers, and molecular confirmation strategy for Prader-Willi Syndrome; this is necessary for curators to evaluate whether the modeled mechanism and phenotype scope match the intended disease. 2. Research-artifact consumption: matching deep-research artifact(s) exist and should be treated as first-class review inputs. Compare the YAML against the artifact(s), especially for central mechanisms, subtype-specific features, treatments/trials, and diagnostic/surveillance details rather than only schema-valid content. 3. Disease-boundary check: no subtypes are modeled. Confirm this is intentionally a single pathomechanism entry and not a spectrum that should expose subtypes, genotype classes, or clinically distinct forms. 4. Pathophysiology review: the main modeled mechanisms include Loss of Paternally Expressed Genes at 15q11.2-q13, SNORD116 as Minimal Critical Region, Hypothalamic Dysfunction, Circadian and Epigenetic Dysregulation. Check that each is an atomic event with direct evidence and that downstream edges do not encode multi-step chains or unsupported causal leaps from gene/product defect to organ-level phenotype. 5. Treatment modeling: treatments are present (Growth Hormone Therapy, Dietary Management, Hormone Replacement Therapy, Diazoxide Choline Extended-Release). Check therapeutic agents, subtype applicability, evidence strength, and surveillance/supportive-care needs; avoid broad treatment claims that are not tied to the relevant phenotype or disease stage. 6. Evidence/reference check: top references include ORPHA:739, PMID:40708003, PMID:12598399, PMID:28659150. Spot-check that snippets directly support the specific claim, frequency, and evidence_source classification, especially where the same PMID is reused across phenotype, mechanism, and treatment assertions. ## Content-Completeness Checklist - Phenotype coverage: review major phenotypes such as Neonatal Hypotonia, Hyperphagia, Obesity, Intellectual Disability, Short Stature. - Subtype completeness: N/A or not modeled; confirm no required subtype split. - Pathophysiology depth: mechanisms present but require atomicity/evidence review. - Treatments and trials: present; verify standard-vs-investigational scope. - Genetics: genetic section present; verify inheritance, variant classes, and genotype-phenotype claims. - Biomarkers/diagnostics: gap noted; diagnosis absent. - References/research consumption: compare the YAML against listed sources and local research artifacts; do not treat retrieval-heavy papers as issues unless they are disease-specific and directly modelable. ## Suggested Remediation Resolve the blocking diagnostic/baseline gaps first, then tighten subtype-specific claims, pathophysiology atomicity, treatment/trial scope, and evidence-to-claim alignment. Keep deterministic schema/term/reference validation separate from this biological review. ## Sources Used - Local research artifact: `research/Prader-Willi_Syndrome-deep-research-openscientist.md` - `ORPHA:739` - PMID:40708003: https://pubmed.ncbi.nlm.nih.gov/40708003/ - PMID:12598399: https://pubmed.ncbi.nlm.nih.gov/12598399/ - PMID:28659150: https://pubmed.ncbi.nlm.nih.gov/28659150/ No YAML files or `references_cache/*.md` files were edited for this review.
Prader-Willi Syndrome (PWS) is a rare, complex genomic imprinting disorder caused by the loss of function of paternally expressed genes on chromosome 15q11.2-q13, with an estimated prevalence of approximately 1 in 10,000 to 30,000 live births. The disorder is characterized by a distinctive biphasic clinical course: severe neonatal hypotonia and feeding difficulties in infancy, followed by the development of insatiable hyperphagia (uncontrollable appetite) typically beginning between ages 2 and 8, which leads to life-threatening obesity if caloric intake is not strictly managed. The central pathophysiological mechanism is hypothalamic dysfunction, which accounts for the majority of clinical features including growth hormone deficiency, hypogonadism, temperature dysregulation, sleep abnormalities, and the hallmark appetite dysregulation.
Among the genes lost in PWS, SNORD116 (a cluster of small nucleolar RNAs) has emerged as the minimal critical region gene, with rare microdeletions confined to SNORD116 alone sufficient to produce the core PWS phenotype. This discovery has fundamentally reshaped the understanding of PWS pathogenesis and has opened new avenues for targeted therapeutics. Current standard of care centers on early growth hormone therapy (which improves body composition, linear growth, and cognitive outcomes) combined with rigorous dietary management and multidisciplinary support. However, the therapeutic landscape is rapidly evolving, with emerging pharmacological agents targeting hyperphagia (diazoxide choline extended-release, oxytocin analogs, GLP-1 receptor agonists) and potentially curative gene-reactivation strategies (antisense oligonucleotides and CRISPR-based epigenome editing to unsilence the maternal copy of SNORD116) representing the most promising frontier.
This report synthesizes evidence from 68 peer-reviewed publications spanning genetics, neuroendocrinology, epidemiology, clinical management, and emerging therapeutics to provide a comprehensive characterization of PWS for researchers and clinicians.
Prader-Willi Syndrome results from the functional absence of genes in the 15q11.2-q13 chromosomal region that are normally expressed only from the paternal allele due to genomic imprinting. The maternal copies of these genes are epigenetically silenced under normal conditions, meaning that any loss of the paternal copy leaves the individual with no functional expression.
Three principal genetic mechanisms account for essentially all cases of PWS:
| Genetic Mechanism | Frequency | Key Features |
|---|---|---|
| Paternal deletion of 15q11.2-q13 | ~65–75% | Two common deletion classes (Type I: BP1–BP3, ~6 Mb; Type II: BP2–BP3, ~5.3 Mb) |
| Maternal uniparental disomy (UPD) of chromosome 15 | ~20–30% | Both copies inherited from mother; increasing prevalence with advanced maternal age |
| Imprinting defects | ~1–3% | Epimutations or microdeletions at the imprinting center (IC) preventing paternal gene activation |
| Balanced translocations | <1% | Rare chromosomal rearrangements disrupting the PWS region |
The key paternally expressed genes in the PWS critical region include MKRN3 (regulates puberty onset), MAGEL2 (involved in hypothalamic function and associated with Schaaf-Yang syndrome when mutated alone), NDN (necdin, a neuronal growth suppressor), SNURF-SNRPN (a bicistronic transcript involved in mRNA splicing), and the SNORD116 snoRNA gene cluster. The imprinting center (IC) located within the SNRPN locus governs the epigenetic regulation of the entire domain.
Genotype-phenotype correlations have been documented: patients with deletions tend to have more severe phenotypes including higher rates of skin picking and more pronounced behavioral issues, while UPD patients show higher verbal IQ but increased risk of psychotic illness in adulthood (PMID: 31920975; PMID: 41683698; PMID: 37386011).
A landmark advance in PWS genetics has been the identification of the SNORD116 (also known as HBII-85) small nucleolar RNA (snoRNA) gene cluster as the single locus whose loss is sufficient to produce the cardinal features of PWS. This was established through the study of rare individuals carrying microdeletions restricted to SNORD116 who nonetheless displayed neonatal hypotonia, feeding difficulties transitioning to hyperphagia, growth hormone deficiency, and cognitive impairment — the hallmark features of PWS.
SNORD116 encodes a cluster of C/D box snoRNAs that function in post-transcriptional RNA processing, though their precise molecular targets remain incompletely characterized. Key mechanistic insights include:
Post-transcriptional regulation: SNORD116 has been shown to post-transcriptionally increase the mRNA stability of NHLH2 (Nescient Helix-Loop-Helix 2), a transcription factor involved in processing prohormone convertase 1 (PC1). Loss of NHLH2 processing leads to downstream deficiencies in the maturation of multiple prohormones, potentially explaining the pleiotropic endocrine phenotype of PWS (PMID: 33856031).
Epigenetic regulation: SNORD116 exhibits diurnal rhythms of DNA methylation in mouse cortex, suggesting a role in circadian epigenetic programming. Loss of Snord116 disrupts these rhythmic methylation patterns, which may contribute to the sleep and circadian disturbances observed in PWS (PMID: 29691382; PMID: 40023766).
Neuronal function: Mouse models with Snord116 deletion show altered cortical neuronal activity, cognitive deficits, and neuronal/endocrine pancreatic developmental phenotypes (PMID: 32426821; PMID: 29800646; PMID: 28973544).
Growth regulation: SNORD116 impacts IGFBP7 (insulin-like growth factor binding protein 7) expression, providing a mechanistic link between the snoRNA cluster and the growth hormone axis abnormalities central to PWS (PMID: 34040195).
A critical case report (PMID: 40231584) described a patient with a deletion including MAGEL2, NDN, and MKRN3 but excluding SNRPN and SNORD116 who did not display the classic PWS phenotype — providing further evidence that SNORD116 is the indispensable gene for the core syndrome.
The hypothalamus serves as the central integrating hub for the diverse clinical manifestations of PWS. Dysfunction of hypothalamic nuclei — particularly the arcuate nucleus (ARC), paraventricular nucleus (PVN), and ventromedial hypothalamus (VMH) — drives the majority of the syndrome's features:
| Clinical Feature | Hypothalamic Mechanism |
|---|---|
| Hyperphagia/obesity | Impaired melanocortin signaling in the ARC; dysregulated ghrelin and satiety pathways |
| Growth hormone deficiency | Reduced GHRH secretion and/or somatotroph dysfunction |
| Hypogonadism | Deficient GnRH pulsatility → low LH/FSH → incomplete pubertal development |
| Temperature dysregulation | Impaired thermoregulatory set point in the preoptic area |
| Sleep disturbances | Altered orexin/hypocretin signaling; central and obstructive sleep apnea |
| Adrenal insufficiency | Possible central ACTH deficiency (reported in subsets of patients) |
| Behavioral disturbances | Serotonergic and oxytocinergic pathway dysfunction |
The oxytocin system has received particular attention, with studies demonstrating reduced numbers of oxytocin-producing neurons in PWS hypothalami and decreased cerebrospinal fluid oxytocin levels (PMID: 9861478). Oxytocin deficiency may contribute to the feeding difficulties in infancy (impaired suckling reflex), social cognition deficits, and possibly altered thermogenesis (PMID: 37367062; PMID: 39194735). However, clinical trials of intranasal oxytocin have yielded mixed results, with a double-blind crossover study showing some improvements in social behavior but no significant effect on hyperphagia (PMID: 28371242; PMID: 39455012).
The ghrelin paradox in PWS — where patients have markedly elevated circulating ghrelin (the "hunger hormone") even in the fed state — remains only partially explained. Emerging evidence points to defective ghrelin receptor signaling and impaired post-prandial suppression mechanisms rather than ghrelin overproduction per se (PMID: 40136445).
Population-based studies provide a detailed picture of the disease burden:
A Swedish register study highlighted that early GH therapy initiation and comprehensive endocrine management are associated with reduced mortality, while untreated comorbidities — particularly cardiovascular risk factors — remain the leading modifiable contributors to premature death (PMID: 40917343; PMID: 37033248).
Growth hormone (GH) therapy, typically initiated in infancy, is the cornerstone pharmacological intervention for PWS and has been shown in a systematic review and meta-analysis to:
Long-term GH therapy has demonstrated sustained benefits, and a nationwide cohort study from Sweden showed that GH-treated PWS patients had lower mortality and reduced incidence of type 2 diabetes compared to untreated patients (PMID: 41224350; PMID: 40917343). However, GH does not address the core hyperphagia, necessitating additional therapeutic approaches.
| Agent | Mechanism | Status | Key Evidence |
|---|---|---|---|
| Diazoxide choline ER | K-ATP channel opener; reduces insulin secretion, modulates hypothalamic signaling | Phase 3 completed; long-term OLE data available | Improvements in hyperphagia scores and BMI stabilization in open-label extension (PMID: 37919617) |
| Oxytocin (intranasal) | Replaces deficient hypothalamic oxytocin | Phase 2/3; mixed results | Some social behavior improvements; no robust hyperphagia effect (PMID: 28371242; PMID: 41091101) |
| GLP-1 receptor agonists (e.g., dulaglutide, semaglutide) | Incretin-mediated appetite suppression | Case reports; trials ongoing | Potential for weight and glycemic management; safety data limited in PWS (PMID: 38840685; PMID: 38321079) |
| Caralluma fimbriata extract | 5-HT2c receptor agonist; appetite suppression | Preclinical (Snord116 mouse model) | Reduced food intake in PWS mouse model (PMID: 30353709) |
The most transformative potential therapies aim to reactivate the silenced maternal copy of SNORD116 (and potentially other PWS-region genes), which is epigenetically intact but transcriptionally repressed:
These gene-reactivation approaches are still in preclinical or early-phase development but represent a potential paradigm shift from symptomatic management to addressing the root genetic cause (PMID: 40409799; PMID: 34828310; PMID: 41677631).
The following integrative model summarizes the pathophysiological cascade in PWS:
GENETIC LESION
│
▼
Loss of paternal 15q11.2-q13 genes
(Deletion / UPD / Imprinting defect)
│
├──► Loss of SNORD116 snoRNAs ──────────────────────────────┐
│ │ │
│ ├──► ↓ NHLH2 mRNA stability │
│ │ │ │
│ │ ▼ │
│ │ ↓ Prohormone convertase 1 (PC1) processing │
│ │ │ │
│ │ ├──► ↓ Mature hormones (GnRH, GHRH, │
│ │ │ CRH, oxytocin, etc.) │
│ │ │ │
│ │ ▼ │
│ │ HYPOTHALAMIC DYSFUNCTION ◄──────────────────────┘
│ │ │
│ │ ├──► Hyperphagia (ARC: ↑ghrelin, ↓satiety)
│ │ ├──► GH deficiency (↓GHRH → short stature)
│ │ ├──► Hypogonadism (↓GnRH → infertility)
│ │ ├──► ↓Oxytocin → social/feeding deficits
│ │ ├──► Thermodysregulation
│ │ └──► Sleep/circadian disruption
│ │
│ └──► Disrupted diurnal DNA methylation
│ → circadian/epigenetic consequences
│
├──► Loss of MAGEL2 ──► Schaaf-Yang–like features
│ (joint contractures, ASD traits)
│
├──► Loss of NDN ──► Neuronal development defects
│
└──► Loss of MKRN3 ──► Altered puberty timing
This model highlights SNORD116 loss as the central driver, with downstream prohormone processing failure as the key molecular mechanism linking the genetic lesion to the pleiotropic hypothalamic phenotype. Contributions from MAGEL2, NDN, and other genes in the region modulate phenotypic severity, particularly for neurodevelopmental and behavioral features.
| Citation | Key Contribution |
|---|---|
| PMID: 37386011 — Imprinting disorders | Comprehensive review of genomic imprinting mechanisms in PWS and related disorders |
| PMID: 37051256 — Prader-Willi and Angelman Syndromes: Mechanisms and Management | Detailed comparison of the two reciprocal imprinting disorders at 15q11-q13 |
| PMID: 41683698 — Clinical Presentation, Genetics, and Laboratory Testing | Integrated review of molecular mechanisms with clinical diagnostic approach |
| PMID: 40409799 — Prader Willi syndrome: advances in genetics | Latest advances including gene reactivation approaches |
| PMID: 40231584 — Case with deletion excluding SNRPN and SNORD116 | Critical evidence that SNORD116 is necessary for PWS phenotype |
| Citation | Key Contribution |
|---|---|
| PMID: 33856031 — Snord116 post-transcriptionally increases Nhlh2 mRNA stability | Mechanistic link between SNORD116 and prohormone processing |
| PMID: 29691382 — Snord116-dependent diurnal rhythm of DNA methylation | Circadian epigenetic role of SNORD116 |
| PMID: 34040195 — SNORD116 and GH therapy impact IGFBP7 | Link between SNORD116, GH axis, and growth regulation |
| PMID: 32426821 — Loss of Snord116 alters cortical neuronal activity | Neurophysiological consequences of Snord116 deletion in mice |
| Citation | Key Contribution |
|---|---|
| PMID: 40136445 — Role of the arcuate nucleus in regulating hunger and satiety in PWS | Detailed analysis of ARC dysfunction in PWS hyperphagia |
| PMID: 9861478 — CSF levels of oxytocin in PWS | Early evidence of oxytocin deficiency |
| PMID: 37685915 — Hormonal imbalances in PWS and Schaaf-Yang syndromes | Comparative neuroendocrine analysis |
| PMID: 36465638 — Adrenal insufficiency in patients with PWS | Under-recognized endocrine complication |
| Citation | Key Contribution |
|---|---|
| PMID: 40708003 — Burden of illness in PWS: systematic literature review | Comprehensive assessment of morbidity, mortality, and healthcare utilization |
| PMID: 41871994 — Epidemiology, comorbidities, and healthcare costs in South Korea | Population-level cost and prevalence data |
| PMID: 40917343 — Long-term impact of GH on mortality and T2DM | Nationwide cohort evidence for GH survival benefit |
| PMID: 40484454 — Health outcomes in European population-based study | Multicentre data on pediatric health outcomes |
| Citation | Key Contribution |
|---|---|
| PMID: 41224350 — Long-term GH effects: systematic review and meta-analysis | Strongest evidence synthesis for GH therapy benefits |
| PMID: 37919617 — Diazoxide choline ER: long-term open-label study | Emerging hyperphagia therapy efficacy data |
| PMID: 28371242 — Oxytocin treatment: double-blind crossover study | Rigorous RCT of oxytocin in PWS children |
| PMID: 36896885 — New avenues for pharmacological management of hyperphagia | Review of emerging drug targets |
Incomplete understanding of SNORD116 molecular targets. While SNORD116 has been identified as the critical gene, its complete repertoire of RNA targets and the precise mechanisms by which its loss leads to hypothalamic dysfunction remain incompletely characterized. Most functional studies rely on mouse models, which may not fully recapitulate the human phenotype.
Genotype-phenotype variability. Significant clinical variability exists even among patients with identical genetic subtypes, suggesting contributions from modifier genes, epigenetic variation, or environmental factors that are poorly understood.
Limited clinical trial data. PWS is a rare disorder, and most therapeutic trials have small sample sizes, limiting statistical power. Many emerging therapies (GLP-1 agonists, gene reactivation) have only case-report or preclinical evidence.
Oxytocin paradox. Despite strong biological rationale, oxytocin replacement therapy has not consistently improved core PWS symptoms. Whether this reflects suboptimal dosing, timing, route of administration, or a more fundamental issue with the oxytocin hypothesis remains unclear.
Long-term outcomes data. While GH therapy has strong evidence for short- and medium-term benefits, truly long-term (decades) outcomes data on mortality, cancer risk, and metabolic health are still accumulating.
Gene reactivation safety. Epigenome editing and ASO approaches to reactivate maternal SNORD116 carry risks of off-target effects, incomplete reactivation, or unintended activation of the neighboring UBE3A gene (whose overexpression causes the Angelman-like dup15q syndrome). The therapeutic window and safety profile require extensive preclinical validation.
Adult PWS population. Most research focuses on pediatric PWS. Adult patients face distinct challenges including psychiatric illness (especially psychosis in UPD patients), progressive obesity-related morbidity, and limited access to specialized care, which are under-studied.
Comprehensive SNORD116 target mapping: Employ CLIP-seq and RNA interactome studies in human iPSC-derived hypothalamic neurons to identify the full spectrum of SNORD116 RNA targets, with particular focus on prohormone processing enzymes and neuropeptide mRNAs.
Multi-omic characterization of PWS hypothalamic neurons: Single-cell RNA-seq and ATAC-seq of iPSC-derived hypothalamic neurons from PWS patients (deletion, UPD, and SNORD116-only microdeletion subtypes) to map transcriptional and epigenetic dysregulation at cellular resolution.
GLP-1 receptor agonist clinical trial: Conduct a randomized, placebo-controlled trial of semaglutide in adolescent/adult PWS patients, with hyperphagia questionnaire scores and body composition as primary endpoints, given promising case reports and the established safety profile of these agents.
Longitudinal natural history study: Establish a multi-center, international longitudinal cohort study tracking PWS patients from infancy through adulthood, systematically collecting clinical, biochemical, and neuroimaging data to better define genotype-phenotype relationships and long-term outcomes.
ASO-mediated maternal SNORD116 reactivation: Advance antisense oligonucleotide programs targeting UBE3A-ATS through IND-enabling preclinical studies, with careful assessment of UBE3A levels to avoid dup15q-like toxicity. Develop companion diagnostics for monitoring target engagement.
CRISPR epigenome editing proof-of-concept: In primate models, validate the safety and efficacy of dCas9-based epigenetic reactivation of maternal SNORD116, with particular attention to tissue specificity (CNS targeting), durability of reactivation, and off-target epigenomic effects.
Combinatorial therapy trials: Test combinations of GH therapy with anti-hyperphagia agents (diazoxide choline, oxytocin analogs, or GLP-1 agonists) to determine whether multi-target approaches can achieve synergistic clinical benefits.
Gene therapy clinical trials: Based on preclinical ASO/CRISPR results, design first-in-human gene reactivation trials with carefully selected patient populations (e.g., young children with confirmed SNORD116-inclusive deletions) and comprehensive safety monitoring.
Precision medicine framework: Develop a genotype-informed treatment algorithm that tailors therapeutic approaches based on the specific genetic mechanism (deletion type, UPD, IC defect) and individual patient characteristics.
Prader-Willi Syndrome stands at an inflection point in its therapeutic history. The identification of SNORD116 as the minimal critical gene, combined with advances in epigenome editing and antisense oligonucleotide technology, has created a realistic path toward addressing the root cause of this devastating disorder. While current management relies on growth hormone therapy and rigorous dietary control, the next decade is likely to see the translation of gene reactivation strategies from bench to bedside, potentially transforming PWS from a lifelong management challenge into a treatable genetic condition.